A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory PrimaryTesticular Lymphoma (PTL)

Protocol: 
AAAQ8904
Phase: 
II

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory PrimaryTesticular Lymphoma (PTL)

The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558). This study will see if treatment with nivolumab increases the chance you will have a positive response (complete or partial) in treating your primary central nervous system lymphoma (PCNSL) or primary testicular lymphoma (PTL). It will also see if nivolumab improves your chances of survival and at delaying the worsening of your PCNSL or PTL (called progression).

Are you Eligible? (Inclusion Criteria)

-Subject must have PCNSL and progressed (or did not respond to) first line of
therapy
-Subject must be able to undergo MRI with contrast
-PCNSL subjects must not have systemic disease
-Subjects must not have intraocular PCNSL without evidence of brain disease

Specialty Area(s)

Immunotherapy

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States

ColumbiaDoctors Midtown
51 West 51st St.
New York, NY 10019
United States